A Multicenter Observational Study of SCCCG-AML 2020 Protocol for Childhood Acute Myeloid Leukemia

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000038039

Enrollment

Unknown

Registered

2020-09-09

Start date

2020-09-10

Completion date

Unknown

Last updated

2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myelocytic leukemia

Interventions

three group by risk creteria:chemotherapy

Eligibility

Sex/Gender

All

Age

No minimum to 16 Years

Inclusion criteria

Inclusion criteria: Newly diagnosed children with AML, no more than 16 years old.

Exclusion criteria

Exclusion criteria: 1. Down's syndrome or other hereditary diseases with AML. 2. APL with t (1517) PML/RARa. 3. MDS transfers or secondary or treatment related AML. 4. Those who died or gave up within 7 days after initiation of induction therapy. 5. Other effection chemotherapy drugs for AML have been used for more than 7 days, excluding low-dose chemotherapy aimed for leukopenia.

Design outcomes

Primary

Measure	Time frame
event free survival;overall survival;	—

Secondary

Measure	Time frame
induce remission rate;minimal residual disease;	—

Countries

China

Contacts

Public ContactLuo Xue-Qun

The First Affiliated Hospital of Sun Yat-Sen Universit

l-xuequn@126.com+86 18902233573

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026